Many experimental findings, though not all of them, show an impaired core-proteasome activity in AD samples [37], suggesting an impairment of the proteasome with ageing followed by an incomplete clearance of tau protein, which is normally soluble and degraded by the proteasome. This evidence concerns the gene MAPT and Alzheimer disease.